---
title: "Weekly Recap | Roivant Sciences +16.86%, closing in on record highs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298794448.md"
description: "Roivant Sciences (ROIV) gained 16.86% this week to close at $40.82, against a 0.8% decline for the S&P 500 — a 17.66 percentage point gap. The four-session week started with a sharp gap up on Tuesday (8 Sep), when the stock hit a high of $42.50 before settling at $41.48. It then eased to $41.81 and $40.94 over the next two days, ending Friday at $40.82. Trading was heavy, with average daily volume of about 12.1m shares, roughly 104% above the 60-day median."
datetime: "2026-09-12T06:42:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298794448.md)
  - [en](https://longbridge.com/en/news/298794448.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298794448.md)
generator: "portal-rs"
---

# Weekly Recap | Roivant Sciences +16.86%, closing in on record highs

## The Week

Roivant Sciences (ROIV) gained 16.86% this week to close at $40.82, against a 0.8% decline for the S&P 500 — a 17.66 percentage point gap. The four-session week started with a sharp gap up on Tuesday (8 Sep), when the stock hit a high of $42.50 before settling at $41.48. It then eased to $41.81 and $40.94 over the next two days, ending Friday at $40.82. Trading was heavy, with average daily volume of about 12.1m shares, roughly 104% above the 60-day median.

## Key Events

The main story was the positive PHocus readout for Mosliciguat in PH-ILD, alongside the unveiling of the ongoing Phase 3 PHrontier study. The news triggered a pre-market scramble on Tuesday, with intraday gains topping 20% and the stock reaching record highs. Jefferies, HC Wainwright and TD Cowen followed with rating updates, shifting the debate from a single data point to Phase 3 validation and the commercial ramp of LISRAYA. Elsewhere in the week, director Meghan FitzGerald disposed of roughly $798,000 in shares, while Virginia Retirement Systems and others bought 61,200 shares.

## Analyst Ratings

Twelve brokers cover ROIV: 9 rate it buy, 2 overweight and 1 hold, with no underweight or sell ratings. The consensus is strong buy, with a target of $45.95, about 12.58% above the current $40.82. Targets range from $37.50 to $55.00, with the spread concentrated at the upper end. The stock ranks 94 out of 506 in its biotech sector, in the upper-middle tier.

## The Week Ahead

The macro calendar is heavy next week: the New York Fed manufacturing index lands on Tuesday (15 Sep), followed on Wednesday (16 Sep) by retail sales, retail sales ex-autos, retail control, import prices and the NAHB housing index, plus weekly EIA crude inventories. For ROIV, the key follow-through is the pace of the Phase 3 PHrontier study after the PHocus data, and whether LISRAYA’s commercial launch can support the rerating.

## In Short

ROIV’s move this week arrived alongside the Mosliciguat PHocus data, with positive broker coverage and a consensus target about 12.6% above spot — that is the pricing anchor for now. Against it, the latest session’s large-lot flow leaned net seller, and valuation remains rich on book value at about 6.97x, with negative trailing P/E, typical of an early-stage pipeline story. The question is whether Phase 3 data and commercial traction keep that narrative intact.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ROIV.US](https://longbridge.com/en/quote/ROIV.US.md)

## Related News & Research

- [61,200 Shares in Roivant Sciences Ltd. $ROIV Bought by VIRGINIA RETIREMENT SYSTEMS ET Al](https://longbridge.com/en/news/298705848.md)
- [Roivant Sciences director Meghan FitzGerald disposes of USD 798,000 in common shares](https://longbridge.com/en/news/298660864.md)
- [Virginia Housing Chief Counsel Fred Bryant Selected for Virginia Lawyers Weekly In-House Counsel Awards](https://longbridge.com/en/news/299351675.md)
- [VIRGINIA RETIREMENT SYSTEMS ET Al Invests $870,000 in Valero Energy Corporation $VLO](https://longbridge.com/en/news/298885953.md)
- [ROIV: PHocus trial data in PH-ILD and LISRAYA's launch highlight major advances and pipeline momentum](https://longbridge.com/en/news/298348190.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**